Background: BRAF mutation occurs in 8-15% of colon cancers (CC), and is associated with poor prognosis in metastatic disease. Compared to wild-type BRAF (BRAFWT) disease, stage II/III CC patients with BRAF mutant (BRAFMT) tumors have shorter overall survival after relapse; however, time-to-relapse is not significantly different. The aim of this investigation was to identify, and validate, novel predictors of relapse of stage II/III BRAFMT CC.
Introduction:
Results from a phase III trial (MRC COIN trial, n=1630) in metastatic CRC revealed that patients with BRAF mutant (BRAFMT) tumors have a significantly worse prognosis compared to patients with KRAS mutant (KRASMT) tumors or tumors with no detectable mutations in KRAS or BRAF (WT/WT). [1] Analysis of tumors in a cohort of 688 stage II and III colon cancer (CC) clinical trial samples (PETACC-3) [2] confirmed that BRAF mutation could identify a subgroups of patients with poorer OS after relapse, (i.e. when the patient had progressed to stage IV metastatic disease). Importantly however, BRAF mutation did not identify stage II/III patients with a higher rate of disease relapse, indicating the poor prognosis of BRAFMT disease was only evident in stage IV disease.
There is currently a lack of understanding of the biology that drives disease relapse, specifically within stage II/III BRAFMT disease. Therefore, we aimed to identify novel predictors of relapse for stage II/III BRAFMT CC, employing transcriptomic datasets for in silico discovery/initial corroboration, followed by subsequent validation of promising lead candidate(s) from bioinformatics analyses by immunohistochemistry analysis within a large D u n n e , C o l e m a n e t a l . P a g e | 5
Patients and methods
Transcriptional datasets
Gene expression profiles were downloaded from NCBI Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE39582 and GSE35602. As detailed in Supplementary Figure 1 , GSE39582 [3, 4] contained 460 stage II/III CC profiles which had relapse data available. For initial biomarker discovery, the "Prognostic Subset"
contained untreated stage II/III patients stratified into high-risk (if the patient relapsed within 36 months) or low-risk (if there was no relapse). The "Initial Consolidation" contained all stage II/III patients with relapse information and mutational data (n=417), which included BRAFMT (n=41; 24 of which will have been used already in the prognostic subset), KRASMT (n=166) or WT/WT (n=210) ( Supplementary Figure 1 ).
Transcriptional analysis
Partek Genomics Suite was employed for dataset analysis. Differentially expressed probesets which had a fold-change +/-1.75 fold and p-value <0.005 were defined using analysis of variance (ANOVA) of supervised risk groupings in both the BRAFMT and D u n n e , C o l e m a n e t a l . P a g e | 6 Results:
Independent stage II/III CC Northern Ireland validation cohort

Study outline and rationale for risk stratification in BRAFMT CC
We analyzed available transcriptional data from the well-characterized dataset, GSE39582
( Supplementary Figure 1 ). Compared to KRASMT and WT/WT, BRAFMT patients were significantly more likely to be older (p<0.001), proximal (p<0.001) exhibit microsatellite instability (MSI, p<0.001) and be assigned as Consensus Molecular Subtype 1 (CMS1, p<0.001) ( Table 1) . Additionally, patients with BRAFMT tumors were significantly more likely to be female (p=0.04 and p=0.001) and receive no adjuvant chemotherapy (p=0.001 and p=0.006) compared to KRASMT and WT/WT respectively ( Supplementary Table 1 ). Finally,
BRAFMT patients were significantly more likely to have earlier stage disease (stage II v III) compared to WT/WT patients (p=0.04) ( Supplementary Table 1 ). Using the 64 gene BRAF classifier identified by Popovici et al. [2] we performed semi-supervised hierarchical clustering of the gene expression profiles of the entire stage II/III patient cohort. We identified a subgroup accounting for 28% (n=127) of the tumor profiles using this method of clustering, which displayed an expression pattern similar to the pred-BRAFm profile ( Supplementary   Figure 2A ). We confirmed no difference in relapse rates between the pred-BRAFm and the pred-BRAFwt populations in this cohort ( Supplementary Figure 2A ; HR=0.95 (95% CI 0.65-1.39)).
Gene expression associated with risk of relapse in BRAFMT CC
GSEA of the discovery subset indicated increased myogenesis, epithelial-to-mesenchymal transition (EMT) and hypoxia pathways in the BRAFMT tumors with the highest-risk of disease relapse ( Supplementary Fig 2B) . Additionally, using the MCP-counter, we identified a non-significant trend for increased fibroblasts in high-risk BRAFMT tumors ( Supplementary   Fig 2C) . Using differential gene expression analysis contrasting profiles from high-risk or low-risk BRAFMT tumors in the discovery subset ( Supplementary Figure 1) , we identified 83 probesets (Supplementary prognostic for relapse risk in BRAFMT tumors; high expression of 43 genes were associated with increased risk of relapse, and high expression of 24 genes with decreased risk of relapse ( Supplementary Table 3 ). Increased expression of endoplasmic reticulum stressinduced transcripts such as PPP1R15A (GADD34), heat shock proteins HSPA6 and DNAJB1, and the stress-related transcription factor DDIT3 were observed in BRAFMT tumours with the highest-risk of disease relapse.
While the majority of the 67 genes are represented by a single probeset, BCL2L1 (encoding Bcl-xL) and NCRNA00275 (which transcribes ZFAS1) are both represented by 3 different probesets, reducing the probability of the single genes themselves being false positives, which could potentially confound the validity of genes identified by a single probeset only (Supplementary Table 2 ). Gene expression levels of Bcl-xL were increased between 1.76-1.97 fold ( Figure 1A ) and ZFAS1 by 1.83 -1.90 fold ( Supplementary Table 2 ) in the high-risk group compared to the low risk group. Importantly, the 67 BRAFMT prognostic gene list is distinct from the BRAFMT transcriptional classifier reported by Popovici, as only one gene, (Kallikrein-Related Peptidase 10 (KLK10)), overlaps between these 2 gene lists (Supplementary Figure 2D ).
Probesets associated with risk in BRAFMT tumors represent distinct novel prognostic biology
As BRAF and KRAS are both key components of the EGFR/MAPK pathway, we performed a similar risk association analysis in KRASMT tumors and identified 139 probesets associated with risk-of-relapse in this genetic subgroup (Supplementary Table 4 ). We found no overlap between the probesets associated with risk-of-relapse in the KRASMT subgroup and the probesets identified in the BRAFMT analyses ( Supplementary Figure 2E ), indicating that distinct biologies determine prognosis in these two subgroups, at least in stage II/III disease. 
Bcl-xL mRNA expression is associated with poor prognosis in stage II/III BRAFMT CC
In order to confirm the genotype-specific prognostic relevance of elevated Bcl-xL gene expression for BRAFMT CC, we next generated an "Initial Consolidation" dataset (n=417, Supplementary Figure 1 ) by removing the filters initially applied to the discovery subset of the GSE39582 cohort, (i.e. we removed the restrictions on chemotherapy treatment and the follow-up criteria as detailed in Methods). This set of 417 patients represents an ideal cohort to assess the prognostic value of Bcl-xL in KRASWT and WT/WT patients that were not used to identify Bcl-xL, in addition to a further 17 BRAFMT patients that were previously excluded from the discovery data. Within BRAFMT tumors (n=41), the Bcl-xL-high group (Bcl-xL high ) had a significantly higher risk-of-relapse compared to the Bcl-xL-low (Bcl-xL low ) expression group, as determined using an unadjusted model (HR=5.83). In line with established clinical findings that MSI tumors are less likely to relapse in early stage disease [3] , we performed an adjusted model (HR=9.63) accounting for potential confounding factors including age, gender, TNM stage and MSI status (confidence intervals could not be calculated due to an absence of events in Bcl-xL low ; Figure 1B and Table 1 ).
When examining untreated patients only, the prognostic value of Bcl-xL mRNA expression in BRAFMT patients was again apparent ( Figure 1C) ; however, the prognostic value of Bcl-xL in the chemotherapy-treated patient subgroup could not be evaluated due to small numbers (n=8). Stratification based on the median also demonstrated the prognostic value of Bcl-xL gene expression (HR=5.24 (95% CI 1.3-21.2)) (Supplementary Figure 3A) .
In contrast, although there was a suggestive prognostic trend, no significant associations were observed for Bcl-xL gene expression in either the KRASMT or WT/WT patient groups, as assessed using either an adjusted or unadjusted analysis model (Table 1 and Supplementary Figures 3B and 3C ). High gene expression of ZFAS1 was associated with a prognostic trend in BRAFMT tumors compared to low gene expression (Supplementary Figure 4A ), although this trend failed to reach significance in either unadjusted HR=4.69 (95% CI 0.52-42.01), or adjusted HR=4.71
ZFAS1 mRNA expression is associated with poor prognosis in stage II/III BRAFMT CC
(95% CI 0.50-44.00) analyses ( Supplementary Table 5 ). There was no prognostic value associated with high ZFAS1 expression in the KRASMT population (adjusted HR=0.65 (95% CI 0.34-1.24)), although there was a significant association with lower relapse rates in the WT/WT population (adjusted HR=0.47 (95% CI 0.24-0.92)) ( Supplementary Figure 4 , Supplementary Table 5 ).
Bcl-xL gene and protein expression are associated with the epithelial component of the tumor
Given the multiple cell types that constitute the tumor microenvironment (TME) in CC, we
analyzed Bcl-xL mRNA expression levels in transcriptional data derived from microdissected tumor tissue (GSE35602). We observed that its expression was bimodal in the epithelial compartment of the TME, with high and low subgroups around the median, whereas stromal expression levels were generally low, with values below the median (Supplementary Figure 5A ). Analysis of matched Bcl-xL transcript abundance (by Agilent microarray) and protein levels (by Reverse Phase Protein Array (RPPA)) from 102 CRC tumor samples within The Cancer Genome Atlas (TCGA) [6] indicated a significant correlation between both methodologies (p=0.001; Supplementary Figure 5B ), supporting protein-based assessment as an appropriate methodology to validate our data in an independent cohort. Following optimization of an IHC protocol for Bcl-xL protein expression, the predominantly epithelial-derived nature of Bcl-xL protein expression and neoplasticspecific staining compared to the normal glands in surrounding tissue was confirmed in a series of whole-face CC sections, although there does appear to be some stromal expression, in line with our transcriptional analysis (Figure 2A ). 
Independent validation of Bcl-xL as a poor prognostic marker specifically in stage II/III BRAFMT CC
We then independently validated the prognostic value of Bcl-xL protein expression specifically in BRAFMT patient samples from within a Northern Ireland cohort (n=661) (Supplementary Figure 1 and described in Methods). Employing tertiles defined by protein expression ( Figure 2B ), we found that in BRAFMT disease Bcl-xL high was associated with an increased risk of CRC disease-specific survival (DSS) when compared with Bcl-xL low , in both unadjusted (HR=3.07 (95% CI 1.24-7.60)) and using an adjusted model to account for MSI status (HR=5.50 (95% CI 1.71-17.69) (Supplementary Figure 6A and Table 2 ). Similar findings were evident when using OS as the endpoint (Supplementary Figure 6B ).
We next conducted stratified analyses within this cohort to assess independently the prognostic value of Bcl-xL protein expression in both untreated and chemotherapy-treated BRAFMT patients. In untreated patients, we observed a 12-fold increased DSS risk in patients with the highest Bcl-xL protein expression (adjusted model accounting for MSI HR=12.13 (95% CI 2.49-59.13)) ( Figure 3A) , which was not observed in treated patients, (adjusted model accounting for MSI HR=0.96 (95% CI 0.08-11.42)) (Supplementary Figure   6C and Table 2 ). This significant prognostic benefit from adjuvant chemotherapy in BRAFMT patients was only observed in patients with the highest Bcl-xL protein expression (P-value for interaction =0.006), whereas patients with low Bcl-xL protein expression derived no benefit from the addition of chemotherapy ( Figures 3B and C , Table 2 and Supplementary Figure 6C ). Similar results were evident when using OS as the endpoint (Supplementary Figure 6D , E and F). Importantly, in agreement with our initial consolidation cohort, we were again able to confirm that the prognostic value of Bcl-xL protein expression was not observed in KRASMT (HR=1.00 (95% CI 0.57-1.77) and WT/WT (HR=1.18 (95% CI 0.67-2.09)) patient samples (Table 4 ). 
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Discussion:
In this study, we set out to identify factors influencing patient prognosis specifically in tumors harboring an oncogenic BRAF mutation. Stratification of a discovery prognostic cohort based on risk-of-relapse identified the Bcl-2 family member, Bcl-xL, as being upregulated at the transcriptional level in BRAFMT tumors from patients who went on to relapse following surgery, compared to those BRAFMT patients who experienced no disease recurrence. We validated the prognostic value of Bcl-xL specifically in BRAFMT tumors in both a consolidation transcriptional cohort and in an independent population-based stage II/III cohort. Importantly, in each validation series, we also confirmed the BRAFMT-specific nature of this association, as the expression of Bcl-xL was not associated with increased risk of disease relapse or death in either KRASMT or WT/WT tumors. Interestingly, we observed that although BRAFMT tumors with high Bcl-xL expression have a poor prognosis, this subgroup also appears to benefit the most from standard adjuvant chemotherapy. BRAFMT stage II/III disease. Interestingly, we found almost no overlap between the genes associated with relapse in BRAFMT and KRASMT tumors, suggesting that although there is constitutive activation of the MAP kinase pathway in both these subgroups, there is clearly distinct prognostic tumor biology associated with these different genotypes.
A recent study using RPPA methodology reported that a mathematical model of Bcl-2 family protein interactions (including Bcl-xL) termed DR_MOMP was prognostic in chemotherapytreated stage III CRC. [7] Moreover, this study found that Bcl-2 family signaling was particularly important in Consensus Molecular Subtypes (CMS) 1 and 3. As the CMS1 subgroup is enriched for BRAFMT disease, this report appears to be in agreement with our current study. However, the individual contribution of Bcl-xL expression to prognosis in CMS1/BRAFMT CRC was not reported.
The reason for the significant benefit from standard chemotherapy of Bcl-xL high BRAFMT CRC is unclear. High Bcl-xL expressing tumors may be "primed" to undergo apoptosis in response to chemotherapy, due to co-expression of pro-apoptotic Bcl-2 family members. [8, 9] . The findings presented both here and by others suggest that BRAFMT driven CRC is more aggressive than BRAFWT disease, but only when the disease has disseminated from the primary site. Interestingly, we observed specific changes in the ER-stress machinery in BRAFMT tumors with the highest-risk of disease relapse, with activation and upregulation of factors including GADD34, heat shock proteins, and stress-related transcription (DDIT3) in our analysis. Additionally, using GSEA, we identify increased hypoxia and EMT signaling in high-risk tumors, again indicating an association with ER stress-activation. Each of these factors have been demonstrated to activate the unfolded protein response (UPR), which in turn has been correlated with a higher risk of metastatic recurrence in breast cancer. [10, 11] In agreement with our findings, upregulation of UPR signaling in disseminated tumor cells from breast cancer, lung cancer and prostate cancer enables both the formation and longterm persistence of metastatic lesions. [10, 11] In addition to activation of the UPR machinery, high Bcl-xL expression may promote survival of invasive tumor cells during the metastatic process; for example Bcl-xL has been reported to be a suppressor of anoikis, [9, 12] which would explain its association with increased risk-of-relapse in the BRAFMT subgroup.
This study has several strengths. We have identified Bcl-xL as a novel predictor of response within a poor prognostic group of CC patient samples, using a robust approach that included validation in an independent cohort using a clinically relevant methodology. The populationbased nature of our validation cohort also means that the results should be generalizable to all stage II/III CRC patients. Additionally, given that IHC and mutational tests for BRAF and KRAS are routinely utilized in the diagnostic work-up of CC patients, the methods we have used here could easily be employed within routine pathology reporting practice. However, we do acknowledge that further work is required to identify an optimal cut-off level of Bcl-xL expression that would allow a more robust classification of low and high expressers for prospective patient stratification.
In conclusion, we have identified and independently validated the prognostic value of Bcl-xL mRNA and protein expression specifically within BRAFMT CC, which should help inform selection of treatment options for high-risk BRAFMT stage II/III patients in the adjuvant disease setting. This approach could prevent the initial relapses, which ultimately contribute to the poor outcomes of patients with this genotype. Data presented here provide compelling evidence that, in addition to BRAF mutational analysis, assessment of Bcl-xL protein expression using routine diagnostic IHC methods can identify both poor prognostic BRAFMT stage II/III CC patients who will benefit from adjuvant therapy and an otherwise good Acknowledgements: Table 3 . Table 4 . 
